Drugs / COPPER OXODOTREOTIDE
COPPER OXODOTREOTIDE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DETECTNET | — | 2020-09-03 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06122610 | Mar 2025 → May 2026 | neuroendocrine neoplasm | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05709171 | Jan 2023 → Jan 2025 | digestive system neuroendocrine neoplasm, neuroendocrine carcinoma | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT05880394 | Jan 2023 → Jul 2024 | breast cancer | Hoag Memorial Hospital Presbyterian | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03673943 | Aug 2018 → Mar 2019 | neuroendocrine neoplasm | Radiomedix, Inc. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06016855 | May 2024 → May 2027 expected | metastatic malignant neoplasm, pancreatic neuroendocrine tumor G1 | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COPPER OXODOTREOTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4302413 ↗ |
| Known as | 64Cu-DOTATATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673943 ↗ |
| Known as | Copper (64cu) dotatate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4302413 ↗ |
| Known as | copper Cu 64 dotatate | “undergo copper Cu 64 dotatate positron emission tomography/CT (dotatate PET/CT) during screening and on study.” NCT06016855 ↗ |
| Known as | Copper dotatate cu-64 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4302413 ↗ |
| Known as | COPPER OXODOTREOTIDE CU-64 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4302413 ↗ |
| Known as | Copper-64 DOTATATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05880394 ↗ |
| Known as | Detectnet | ChEMBL registry synonym — accepted as the source's own label CHEMBL4302413 ↗ |
| Modality | Peptide | “This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.” NCT03673943 ↗ |
| Route | Other | “after injection of 64Cu-Dotatate” NCT05709171 ↗ |